Phoenix Financial Ltd. Raises Stake in Johnson & Johnson $JNJ

Phoenix Financial Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 31,106 shares of the company’s stock after acquiring an additional 4,058 shares during the period. Phoenix Financial Ltd.’s holdings in Johnson & Johnson were worth $4,755,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GFG Capital LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $191.93 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The firm has a market capitalization of $462.23 billion, a P/E ratio of 18.53, a PEG ratio of 2.28 and a beta of 0.40. The company’s fifty day moving average is $181.27 and its two-hundred day moving average is $165.37.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. HSBC increased their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $200.06.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.